Compare T Rowe Price Group Inc (TROW) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T Rowe Price Group Inc vs Viatris Inc — how do they compare? T Rowe Price Group Inc trades at $115.59 (market cap $25.14B), while Viatris Inc trades at $17.15 (market cap $19.79B). The key difference: T Rowe Price Group Inc is the larger of the two by market cap, and T Rowe Price Group Inc pays the higher dividend (4.43%). Which is the better fit depends on your goals.
| TROW | VTRS | |
|---|---|---|
Market Cap | $25.14B | $19.79B |
Sector | Financials | Health |
52-Week High | $120.16 | $17.39 |
52-Week Low | $86.19 | $8.74 |
Enterprise Value | $21.85B | $32.00B |
Dividend Yield | 4.43% | 2.83% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
